Avacopan in Anti-Neutrophil Cytoplasmic Autoantibodies–Associated Vasculitis in a Real-World Setting

Anti-neutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) represents a group of systemic autoimmune small vessel vasculitis, leading to significant morbidity and mortality due to extensive organ damage (including kidney failure)1 and treatment toxicity to medications such as glucocorticoids.2 Thus, research focuses on developing treatment that minimize glucocorticoid use.